Quotient (QTNT) Given Media Sentiment Rating of 0.00
News stories about Quotient (NASDAQ:QTNT) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Quotient earned a media sentiment score of 0.00 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 43.4574773543938 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several analysts recently issued reports on QTNT shares. ValuEngine downgraded shares of Quotient from a “sell” rating to a “strong sell” rating in a report on Friday, May 18th. Zacks Investment Research lowered shares of Quotient from a “hold” rating to a “strong sell” rating in a report on Saturday, June 2nd. BidaskClub raised shares of Quotient from a “hold” rating to a “buy” rating in a report on Thursday, June 21st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Quotient in a report on Wednesday, May 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Quotient currently has an average rating of “Hold” and a consensus price target of $11.50.
NASDAQ:QTNT traded up $0.10 during mid-day trading on Monday, reaching $7.20. 2,741 shares of the company were exchanged, compared to its average volume of 211,258. Quotient has a 12 month low of $2.78 and a 12 month high of $9.02. The company has a quick ratio of 1.59, a current ratio of 2.11 and a debt-to-equity ratio of -3.11. The firm has a market cap of $384.27 million, a P/E ratio of -3.56 and a beta of 0.17.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
See Also: Are analyst ratings accurate?
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.